Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Hold” by Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $22.50.

DCTH has been the subject of several recent research reports. Zacks Research downgraded shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in DCTH. California State Teachers Retirement System purchased a new stake in shares of Delcath Systems during the second quarter valued at approximately $26,000. Russell Investments Group Ltd. purchased a new position in shares of Delcath Systems in the 3rd quarter worth about $29,000. Tower Research Capital LLC TRC bought a new position in Delcath Systems during the second quarter valued at about $40,000. Legal & General Group Plc bought a new position in Delcath Systems during the second quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Delcath Systems during the second quarter worth about $151,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $13.20 on Friday. The company has a fifty day simple moving average of $11.41 and a 200 day simple moving average of $10.40. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $13.44. The company has a market cap of $455.66 million, a P/E ratio of 1,320.00 and a beta of 0.49.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.07. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. The firm had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. Sell-side analysts predict that Delcath Systems will post -0.88 EPS for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.